{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:04:54Z","timestamp":1778645094570,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106091","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T02:20:21Z","timestamp":1772677221000},"page":"106091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-1254","authenticated-orcid":false,"given":"K.","family":"Jhaveri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"F.C.","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-7902","authenticated-orcid":false,"given":"K.","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"S.M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"Litchfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9770-7896","authenticated-orcid":false,"given":"C.C.","family":"von Laue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-2737","authenticated-orcid":false,"given":"S.","family":"Traore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sapunar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2026.106091_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106091_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/cancers16030619","article-title":"Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer","volume":"16","author":"Neupane","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.106091_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9:","author":"Patel","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.106091_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102670","article-title":"Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"123","author":"Jhaveri","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106091_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106091_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2026.106091_bib7","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2026.106091_bib8","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.esmoop.2026.106091_bib9","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","article-title":"Fulvestrant: pharmacokinetics and pharmacology","volume":"90","author":"Robertson","year":"2004","journal-title":"Br J Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.esmoop.2026.106091_bib11","article-title":"Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model [abstract]","volume":"8","author":"VandeKopple","year":"2023","journal-title":"ESMO Open"},{"issue":"Suppl 13","key":"10.1016\/j.esmoop.2026.106091_bib12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1538-7445.AM2021-1236","article-title":"Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD) [abstract]","volume":"81","author":"Bhagwat","year":"2021","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106091_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106091_bib16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106091_bib17","article-title":"Abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: final overall survival results from MONARCH 2","volume":"2","author":"Neven","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106091_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106091_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106091_bib20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106091_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"issue":"Suppl 16","key":"10.1016\/j.esmoop.2026.106091_bib23","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2025.43.16_suppl.1001","article-title":"Patient-reported outcomes (PROs) in patients with ER+, HER2\u2212 advanced breast cancer (ABC) treated with imlunestrant, investigator\u2019s choice standard endocrine therapy, or imlunestrant + abemaciclib: results from the phase III EMBER-3 trial [abstract]","volume":"43","author":"Curigliano","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106091_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/cer-2020-0272","article-title":"Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive\/HER2-negative advanced breast cancer","volume":"10","author":"Rugo","year":"2021","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.esmoop.2026.106091_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2147\/CMAR.S163478","article-title":"Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2\u2212 advanced breast cancer","volume":"10","author":"Tremblay","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106091_bib26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"Suppl 4","key":"10.1016\/j.esmoop.2026.106091_bib27","article-title":"6MO Baseline ctDNA and methylation status as predictors of treatment benefit in the phase III post MONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients [abstract]","volume":"10","author":"Wander","year":"2025","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106091_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 16","key":"10.1016\/j.esmoop.2026.106091_bib29","article-title":"evERA Breast Cancer (BC): phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2\u2212 LA\/mBC) [abstract]","volume":"41","author":"Mayer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"10.1016\/j.esmoop.2026.106091_bib30","volume":"43","author":"Llombart-Cussac","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"10.1016\/j.esmoop.2026.106091_bib31","volume":"42","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:14:28Z","timestamp":1774487668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926000335"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106091","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106091"}}